Absolute Bioavailability Study With Bexagliflozin

Withdrawn before enrolling · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.

Key facts

Study ID

NCT03417076

Run by

Theracos

People needed

0

Starts

2018-08-01

Expected to finish

2018-09-16

Last updated by the study team

2019-09-30

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2
• no nicotine and tobacco consumption in the past 3 months
• willing and able to be confined to the clinical research facility as required by the protocol

You may not qualify if…

• clinically significant history of allergy to drugs or latex
• history of alcohol or drug dependence in the past 12 months.
• donation of a significant amount of blood in the past 2 months
• willing to use an adequate form of birth control during the study and for 90 days after discharge from clinic
• exposure to investigational drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer

Where it is running

• Clinical Research Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.